Martine Piccart

Martine Piccart

UNVERIFIED PROFILE

Are you Martine Piccart?   Register this Author

Register author
Martine Piccart

Martine Piccart

Publications by authors named "Martine Piccart"

Are you Martine Piccart?   Register this Author

100Publications

3808Reads

45Profile Views

Tumor dormancy at bedside: A late awakening.

Breast 2019 Jun 2;45:61-63. Epub 2019 Mar 2.

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.03.001DOI Listing
June 2019

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Curr Treat Options Oncol 2019 Apr 1;20(5):37. Epub 2019 Apr 1.

Department of Research, Institut Jules Bordet; Université Libre de Bruxelles, Boulevard de Waterloo, 121 1000, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0633-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0633-6DOI Listing
April 2019

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Ther Adv Med Oncol 2019 25;11:1758835919827714. Epub 2019 Feb 25.

Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Bruxelles, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919827714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393951PMC
February 2019

Progress in adjuvant systemic therapy for breast cancer.

Nat Rev Clin Oncol 2019 01;16(1):27-44

Research Department, Institut Jules Bordet, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0089-9DOI Listing
January 2019

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?

NPJ Breast Cancer 2019 4;5. Epub 2019 Jan 4.

1Department of Research, Institut Jules Bordet; Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-018-0098-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320365PMC
January 2019

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

J Natl Cancer Inst 2018 10;110(10):1142-1143

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy029DOI Listing
October 2018

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

J Natl Cancer Inst 2018 10;110(10):1115-1122

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro," Department of Clinical Sciences and Community Health, University of Milan, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy042DOI Listing
October 2018

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.

ESMO Open 2018 24;3(6):e000440. Epub 2018 Oct 24.

Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212674PMC
October 2018

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Cancer Treat Rev 2018 Jun 2;67:10-20. Epub 2018 May 2.

Research Department, Institut Jules Bordet, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.016DOI Listing
June 2018

Neoadjuvant treatment: the future of patients with breast cancer.

ESMO Open 2018 17;3(4):e000371. Epub 2018 May 17.

Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976132PMC
May 2018

Recurrence dynamics of breast cancer according to baseline body mass index.

Eur J Cancer 2017 12 31;87:10-20. Epub 2017 Oct 31.

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.007DOI Listing
December 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

N Engl J Med 2017 Jul 5;377(2):122-131. Epub 2017 Jun 5.

From the German Breast Group, Neu-Isenburg, Germany (G.M.); Frontier Science (Scotland), Kincraig, United Kingdom (M. Procter); the Breast European Adjuvant Study Team (BrEAST) Data Center (E.A., N.R.), the Breast International Group (D.Z., A.A.), and Institut Jules Bordet, Université Libre de Bruxelles (M. Piccart) - all in Brussels; Roche Pharma (M.B., E.C., A.K.) and the Department of Cardiology, Cardio-Oncology, Bern University Hospital (T.S.) - both in Bern, Switzerland; the Department of Pathology, European Institute of Oncology, University of Milan, Milan (G.V.); the National Institute of Oncology, Budapest, Hungary (I.L.); Centre François Baclesse, Caen, France (C.L.); the Sarah Cannon Research Institute and Tennessee Oncology, Nashville (D.A.Y.); Instituto Nacional de Câncer, Rio de Janeiro (J. Bines); Dana-Farber Cancer Institute, Harvard Medical School, Harvard T. H. Chan School of Public Health, and Frontier Science and Technology Research Foundation - all in Boston (R.D.G.); and the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (J. Baselga).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1703643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020PMC
July 2017

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.

Clin Cancer Res 2017 Jun 9;23(11):2702-2712. Epub 2016 Nov 9.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brusells, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0979DOI Listing
June 2017

Unusual presentation of nasopharyngeal carcinoma with rectal metastasis.

World J Clin Cases 2017 May;5(5):183-186

Malvine Vogel, Yassine Lalami, Oncology Department, Jules Bordet Institute, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v5.i5.183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434318PMC
May 2017

Cancer drugs, survival and ethics: a critical look from the inside.

ESMO Open 2016 10;1(6):e000149. Epub 2017 Feb 10.

BrEAST Data Center, Institut Jules Bordet, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419213PMC
February 2017

Targeted adjuvant therapy in breast cancer.

Expert Rev Anticancer Ther 2016 Dec 27;16(12):1263-1275. Epub 2016 Oct 27.

c Institut Jules Bordet, Université Libre de Bruxelles , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2016.1247698DOI Listing
December 2016

70-Gene Signature in Early-Stage Breast Cancer.

N Engl J Med 2016 12;375(22):2200-2201

Institut Jules Bordet, Brussels, Belgium

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1612048DOI Listing
December 2016

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

J Geriatr Oncol 2016 11 26;7(6):463-470. Epub 2016 May 26.

Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, 1 rue Héger Bordet, 1000 Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2016.05.001DOI Listing
November 2016

Endocrine treatment in breast cancer: Cure, resistance and beyond.

Cancer Treat Rev 2016 Nov 7;50:68-81. Epub 2016 Sep 7.

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.08.008DOI Listing
November 2016

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

J Natl Cancer Inst 2016 08 20;108(8). Epub 2016 Apr 20.

Department of Medicine, Breast European Adjuvant Study Team (BrEAST) Data Centre, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium (AS, EdA, MP, HAAJr); Frontier Science (Scotland) Ltd, Grampian View, Kincraig, Kingussie, UK (DAt, IB, CC); Novartis Pharmaceuticals Corporation, East Hanover, NJ (YH); Alliance Statistics and Data Center, Mayo Clinic, Section of Biostatistics, Scottsdale, AZ (ACD); Sunnybrook Odette Cancer Centre, the University of Toronto and the NCIC Clinical Trials Group, Toronto, Ontario, Canada (KIP); The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (ACW); Sana Klinikum Offenbach, Offenbach, Germany (CJ); National Institute of Oncology, Budapest, Hungary (IL); Helios Klinikum Berlin-Buch, Berlin, Germany (MU); Royal Marsden Hospital NHS Trust, Sutton/Surrey, UK (IS); Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, North Sydney, Australia (FB); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (BX); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (HG); Mayo Clinic, Jacksonville, FL (EAP)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017935PMC
August 2016

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

N Engl J Med 2016 Aug;375(8):717-29

From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (L.J.V.); European Organization for Research and Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - all in France; Swiss Institute of Bioinformatics and University of Lausanne, Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1602253DOI Listing
August 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

JAMA Oncol 2016 Feb;2(2):217-24

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium2Medical Oncology Clinic, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4377DOI Listing
February 2016

Breast cancer in 2015: Academic research sheds light on issues that matter to patients.

Nat Rev Clin Oncol 2016 Feb 20;13(2):67-8. Epub 2016 Jan 20.

Department of Hematology and Oncology, Hôpital du Sacré-Cœur de Montréal/Université de Montréal, 5400 Boulevard Gouin, Montreal, Quebec H4J 1C5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.236DOI Listing
February 2016

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Breast Cancer Res Treat 2016 Jan 26;155(1):127-32. Epub 2015 Dec 26.

Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10549-015-36
Web Search
http://link.springer.com/10.1007/s10549-015-3656-0
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3656-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947530PMC
January 2016

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Breast 2015 Nov 5;24 Suppl 2:S143-8. Epub 2015 Aug 5.

Institut Jules Bordet, Université Libre des Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.034DOI Listing
November 2015

Neoadjuvant therapy for breast cancer.

Annu Rev Med 2015 27;66:31-48. Epub 2014 Oct 27.

Breast International Group Headquarters (BIG-aisbl), Brussels 1000, Belgium; email: ,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-051413-024741DOI Listing
September 2015

New approaches for improving outcomes in breast cancer in Europe.

Breast 2015 Aug 31;24(4):321-30. Epub 2015 Mar 31.

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.03.001DOI Listing
August 2015

Clinical management of breast cancer heterogeneity.

Nat Rev Clin Oncol 2015 Jul 21;12(7):381-94. Epub 2015 Apr 21.

Jules Bordet Institute, Boulevard de Waterloo 121, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.73DOI Listing
July 2015

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.

J Med Case Rep 2015 Feb 12;9. Epub 2015 Feb 12.

Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Boulevard de Waterloo 125, B-1000, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1752-1947-9-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429498PMC
February 2015

An update on PARP inhibitors--moving to the adjuvant setting.

Nat Rev Clin Oncol 2015 Jan 7;12(1):27-41. Epub 2014 Oct 7.

BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 125, B-1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.163DOI Listing
January 2015

Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics".

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Oct 7.

Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel (NIC); Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (EGEdV); Kellog School of Management and Northwestern University Medical School, Chicago, IL (LE); Sussex Health Outcomes Research & Education in Cancer (SHORE-C),Brighton & Sussex Medical School, University of Sussex, Falmer, UK (LF); Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (PAF); Department of Oncology, Shaare Zedek Medical Center, and Hebrew University-School of Medicine, Jerusalem, Israel (AG); Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium (MJP); Department of Otolaryngology and Oncology, Johns Hopkins University, Baltimore, MD (DS); Oncotest/Verify, Teva Pharmaceutical Industries, Petach Tikva, Israel (LS-G); Melabev Community Elders Care Research Department, Jerusalem, Israel (CT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568994PMC
December 2014

New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors.

Clin Cancer Res 2014 Dec 21;20(24):6242-6. Epub 2014 Oct 21.

BrEAST Data Center, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1086DOI Listing
December 2014

Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Nov 7.

Department of Surgery and GROW School for Oncology and Developmental Biology (MM, MLS), Department of Surgery and Radiology (LMvR), Department of Medical Oncology, GROW School for Oncology and Developmental Biology (VCGTH), and Department of Epidemiology and GROW School for Oncology and Developmental Biology (ACV), Maastricht University Medical Center, Maastricht, the Netherlands; Department of Surgery, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands (LJAS); Division of Medical Oncology, Luzerner Kantonsspital, Lucerne, Switzerland (SA); Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian (DAC), Edinburgh Breast Unit (JMD), Western General Hospital, Edinburgh, UK; Cedars-Sinai Medical Center, Los Angeles, CA (AEG); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (BGH); Mater Centre Radiation Oncology Service, Princess Alexandra Hospital, Brisbane, Australia (BEH); Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College, New York, NY (CAH); University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock, AR (VSK); Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia (BK); Interdisciplinary Breast Centre, Department of Gynaecology and Obstetrics, Klinikum Esslingen, Germany (TK); University of Miami Miller School of Medicine, Miami, FL (MEL); Radiation Oncology (BDS) and Department of Surgical Oncology, Division of Surgery (AL), University of Texas/MD Anderson Cancer Center, Houston, TX; Institut Jules Bordet, Université Libre de Bruxelles, Head of Medicine Department, Brussels, Belgium (MP); Surgery, University Medical Center, Leiden, the Netherlands (CJHvdV); Breast Service, Memorial Sloan-Kettering Cancer Center, Evelyn Lauder Breast Center, New York, NY(KJVZ); Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium (JBV); Department of Pathology, European Institute of

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357796PMC
December 2014

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.

Eur J Cancer 2014 Dec 19;50(18):3089-97. Epub 2014 Oct 19.

Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121 (7th Floor), 1000 Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.09.011DOI Listing
December 2014

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Cancer Treat Rev 2014 Oct 12;40(9):1089-95. Epub 2014 Aug 12.

BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.07.005DOI Listing
October 2014

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

J Clin Oncol 2014 Sep 21;32(25):2794-803. Epub 2014 Jul 21.

Felipe Ades, Lina Pugliano, Debora Fumagalli, Evandro de Azambuja, Christos Sotiriou, and Martine Piccart, Institut Jules Bordet, Université Libre de Bruxelles; Dimitrios Zardavas, Breast International Group, Brussels, Belgium; Ivana Bozovic-Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; and Giuseppe Viale, European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1870DOI Listing
September 2014

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Breast 2014 Aug 24;23(4):473-81. Epub 2014 Apr 24.

Breast Cancer Translational Research Laboratory JC Heuson, Institut Jules Bordet, Boulevard de Waterloo 125, Brussels, Belgium; Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.03.012DOI Listing
August 2014

Biology of breast cancer during pregnancy using genomic profiling.

Endocr Relat Cancer 2014 Aug 13;21(4):545-54. Epub 2014 May 13.

Department of MedicineInstitut Jules Bordet, BrEAST Data Centre, Université Libre de Bruxelles (ULB), Boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory (BCTL) J. C. HeusonInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BelgiumDepartment of MedicineInstitut Jules Bordet, BrEAST Data Centre, Université Libre de Bruxelles (ULB), Boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory (BCTL) J. C. HeusonInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxel

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-14-0111DOI Listing
August 2014

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Breast Cancer Res Treat 2014 Jun 13;145(2):411-8. Epub 2014 Apr 13.

Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Cancer Research Centre, Sheffield, S10 2SJ, England, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-2939-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025174PMC
June 2014

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

J Clin Oncol 2013 12 18;31(36):4504-11. Epub 2013 Nov 18.

Jose Baselga, Memorial Sloan-Kettering Cancer Center, NY; James G. Greger Jr, GlaxoSmithKline, Collegeville, PA; Hatem A. Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles; Phuong Dinh, Breast International Group, Brussels; Peter Vuylsteke, Sint-Elisabeth Hospital, Namur, Belgium; Dominique Agbor-tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland; Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom; Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Christian Jackisch, Kilinikum Offenbach, Offenbach; Bahriye Aktas, Kliniken Essen-Mitte, Evang, Essen; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Chiun-Sheng Huang, National Taiwan University Hospital; Ruey Kuen Hsieh, Mackey Memorial Hospital, Taipei, Taiwan; and Lydia Dreosti, University of Pretoria, Pretoria, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.9448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795667PMC
December 2013

Why your preferred targeted drugs may become unaffordable.

Cancer Res 2013 Oct 23;73(19):5849-51. Epub 2013 Sep 23.

Author's Affiliation: Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1486DOI Listing
October 2013